Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free SYRS Stock Alerts

Syros Pharmaceuticals (SYRS) Competitors

Syros Pharmaceuticals logo
$0.0001 0.00 (0.00%)
As of 07/24/2026 03:58 PM Eastern
Compare

SYRS vs. TRVN, NAVB, GNCA, PXMD, and ARDS

Should you buy Syros Pharmaceuticals stock or one of its competitors? MarketBeat compares Syros Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Syros Pharmaceuticals include Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), PaxMedica (PXMD), and Aridis Pharmaceuticals (ARDS). These companies are all part of the "pharmaceutical products" industry.

How does Syros Pharmaceuticals compare to Trevena?

Trevena (NASDAQ:TRVN) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

13.6% of Trevena shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 2.7% of Trevena shares are held by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Trevena's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Trevena Neutral
Syros Pharmaceuticals Neutral

Trevena's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Syros Pharmaceuticals N/A -3,369.56%-97.04%

Trevena has higher revenue and earnings than Syros Pharmaceuticals. Trevena is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A

Trevena has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

Summary

Syros Pharmaceuticals beats Trevena on 6 of the 10 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Syros Pharmaceuticals Neutral

Navidea Biopharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Syros Pharmaceuticals N/A -3,369.56%-97.04%

Summary

Navidea Biopharmaceuticals beats Syros Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Genocea Biosciences' return on equity of -182.88% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Syros Pharmaceuticals N/A -3,369.56%-97.04%

Genocea Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Genocea Biosciences has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Syros Pharmaceuticals Neutral

Summary

Genocea Biosciences beats Syros Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

PaxMedica has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Syros Pharmaceuticals Neutral

PaxMedica's return on equity of -3,167.89% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Syros Pharmaceuticals N/A -3,369.56%-97.04%

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

PaxMedica has higher earnings, but lower revenue than Syros Pharmaceuticals. PaxMedica is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A

Summary

Syros Pharmaceuticals beats PaxMedica on 7 of the 9 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to Aridis Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Aridis Pharmaceuticals has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.31N/A

Aridis Pharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
Aridis Pharmaceuticals N/A N/A N/A

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Syros Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 47.59, suggesting that its share price is 4,659% more volatile than the broader market.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
Aridis Pharmaceuticals Neutral

Summary

Aridis Pharmaceuticals beats Syros Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Get Syros Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SYRS vs. The Competition

Export
MetricSyros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3K$966.39M$6.88B$12.26B
Dividend YieldN/A4.84%2.67%9.79%
P/E Ratio0.001.5326.9923.71
Price / Sales0.01109.17493.8676.90
Price / CashN/A20.0650.5459.64
Price / Book0.008.4810.286.07
Net Income-$164.57M-$3.23M$3.60B$331.84M
7 Day PerformanceN/A-2.80%-1.25%-1.53%
1 Month PerformanceN/A-4.40%-0.35%-2.46%
1 Year PerformanceN/A28.83%18.41%13.66%

Syros Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SYRS
Syros Pharmaceuticals
N/A$0.00
flat		N/A-99.5%$3K$386KN/A120
TRVN
Trevena
N/A$0.01
flat		N/A-98.8%$11K$443KN/A40
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
PXMD
PaxMedica
N/A$0.00
flat		N/A+400.0%$6KN/AN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SYRS) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel